查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466086

药物发现中的人工智慧市场：按产品、技术、流程、应用、治疗领域和最终用户划分 - 2024-2030 年全球预测

Artificial Intelligence in Drug Discovery Market by Offering (Services, Software), Technology (Context-Aware Processing, Machine Learning, Natural Language Processing), Process, Application, Therapeutic Area, End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

人工智慧在药物发现市场规模预计2023年为10.8亿美元，2024年达到13.5亿美元，预计2030年将达到58.1亿美元，复合年增长率为27.10%。

药物发现中的人工智慧是指机器学习演算法和人工智慧系统在发现、设计和优化新药物化合物过程中的应用。这些人工智慧模型将在简化传统上复杂且耗时的药物发现过程中发挥至关重要的作用，推动医学领域的进步。推动市场成长的因素是全球慢性病负担日益加重，以及生物製药公司越来越多地采用人工智慧来提高药物发现的准确性、速度和有效性。此外，管理临床前研究期间产生的大量资料的需求不断增长也推动了市场的成长。医疗保健领域对技能熟练的人工智慧专业人员的需求以及与人工智慧实施相关的高成本正在影响成长的极限。资料集的可用性有限是限制人工智慧在药物发现领域发展的关键挑战。新药发现机制和个人化医疗相关领域存在商机。快速发展的人工智慧药物开发研究领域的技术进步为增强药物发现、疾病理解和患者特异性治疗创造了潜力。

主要市场统计
基准年[2023] 10.8亿美元
预测年份 [2024] 13.5亿美元
预测年份 [2030] 58.1亿美元
复合年增长率（%） 27.10%

所提供的人工智慧软体为药物发现提案了革命性的方法

在药物发现领域，人工智慧 (AI) 提供了广泛的服务，可以加快流程、提高精确度并最终改善结果。这些服务主要包括结构分析、药物重新定位和动态建模。人工智慧软体推动了药物发现的数位革命。由于将人工智慧融入药物发现，出现了各种软体解决方案。这些软体包括预测分析、分子对接、精准医学以及建模和分析软体，可加速患者与最有效药物的匹配。

技术：扩大情境感知处理在个人化治疗的采用

人工智慧演算法交叉引用遗传资料、生物标记和疾病指标，以提案潜在的药物标靶和量身定制的治疗方法。机器学习也是人工智慧的一个分支，它透过预测化合物特性和患者反应以及增强药物设计来促进非编程和智慧决策。另一方面，自然语言处理利用人类语言的力量进行资料挖掘，吸收学术来源的资讯以增强资料的整体性。情境处理提供个人化的治疗方法提案，机器学习推动药物设计的最佳化。相反，自然语言处理利用大型资料集来识别新药和疾病之间的关联。这些技术不是孤立地发挥作用，而是具有融合的潜力，为准确、快速的药物发现提供了希望。

透过过程计算和预测能力显着增强药物发现过程

在药物发现领域的人工智慧 (AI) 领域，候选药物的选择和检验是稳健评估有前途的候选药物的潜在成功的关键步骤。人工智慧演算法分析分子结构，预测其效果，并确定其可行性。下一步涉及识别和优先考虑命中，并从人工智慧筛检上准备一份有前途的候选药物清单。根据效力、选择性和安全性对这些命中进行优先排序。在命中识别之后，命中到先导化合物识别或先导生成阶段的重点是将“命中”转化为“先导化合物”，即可以进一步优化的潜在候选药物。在这里，人工智慧透过测试和优化化合物来帮助药物化学家评估和优化先导化合物。下一步是先导化合物优化，增强潜在的候选药物以提高活性、特异性和安全性。这个阶段需要先进的人工智慧技术来预测潜在的副作用和提高药物疗效的方法。药物发现过程还涉及标靶识别和选择，其中涉及药物缓解疾病标靶的选择。最后一步是标靶检验，检验所选标靶在疾病进展中的作用及其受药物调节的潜力。人工智慧透过计算和预测能力增强每一步，继续彻底改变药物发现。人工智慧大大提高了药物发现的效率，增加了将救命药物更快推向市场的可能性。

应用人工智慧设计的小分子药物在人体临床试验中的使用正在扩大。

生技药品中的分子标靶药物正在利用人工智慧进行更快、更准确的优化，AlphaFold 已经展示了显着的蛋白质预测能力，可以加速药物发现。人工智慧演算法透过更准确地破解模式来增强疾病识别和评估，从而实现早期疗育。药物开发中的安全性、毒性和合规性检查利用人工智慧来预测毒性、提高安全性并降低成本。在 COVID-19 中，高效的疫苗设计和优化至关重要，人工智慧驱动的病毒致病区域识别将有助于这一过程。因此，人工智慧对于製药创新至关重要，有助于识别疾病、设计治疗方法并确保安全合规。

治疗领域：在个人化癌症治疗的药物发现中更多地采用人工智慧。

人工智慧 (AI) 正在成为心血管疾病管理领域的变革性工具，从早期检测到个人化药物製造。人工智慧应用越来越多地用于免疫肿瘤学，以帮助分类和预测治疗反应。公司和研究机构正在利用人工智慧彻底改变对从糖尿病到肥胖等代谢疾病的理解和治疗。人工智慧在帮助诊断和开发神经退化性疾病治疗方法方面的潜力已得到整个领域的认可。

最终用户：製药和生物技术公司更多地使用人工智慧来加速药物发现过程

委外研发机构(CRO) 正在利用人工智慧显着增强药物发现服务并提供高品质、高效的结果。从事人工智慧药物发现的 CRO 通常更喜欢旨在简化工作流程、加快药物发现速度并最大限度地减少人为错误的解决方案。製药和生物技术公司是药物发现背后的驱动力，它们对人工智慧表现出了相当大的亲和性。人工智慧正在透过加快药物发现过程、预测药物反应以及降低与药物失败相关的成本来帮助这些产业。

研究中心、学术和政府机构越来越多地利用人工智慧在药物发现中的潜力。这里的偏好在于人工智慧能够预测潜在的候选药物，最大限度地减少试验的案例，并吸收大量资料进行精确研究。虽然人工智慧的使用程度会根据最终用户的不同而有所不同，但其正面影响是不可否认的。人工智慧透过其准确性、速度和成本效益彻底改变药物发现的潜力正在得到整个领域的日益认可。

区域洞察

美国处于将人工智慧融入药物发现的前沿，拥有充满活力的Start-Ups环境和强大的政府资助。加拿大也响应了这项奉献精神，对人工智慧主导的药物发现平台进行了大量投资。在学术机构和製药业之间的战略合作的推动下，英国、法国和德国等欧洲国家正在利用人工智慧和资料科学彻底改变药物发现程序。以中国、日本和印度为首的亚太地区提供了引人注目的动力。中国大规模的人工智慧投资，加上日本出色的药物研究，正在推动人工智慧在药物发现的应用。在印度，政府的支持和不断发展的 IT 部门正在推动人工智慧在药物发现领域的发展。美国、中国和欧盟在与人工智慧药物发现相关的专利申请方面处于领先地位，代表了各自製药业的持续创新。

FPNV定位矩阵

FPNV定位矩阵对于评估药物发现市场中的人工智慧至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对药物发现市场中的人工智慧供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1. 人工智慧在药物发现领域的市场规模和预测是多少？

2.在药物发现市场的人工智慧预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3. 人工智慧市场在药物发现的技术趋势和法规结构是什么？

4.人工智慧药物发现市场主要供应商的市场占有率是多少？

5.药物发现领域进入人工智慧市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 药物发现过程中对控制和降低成本的需求
      • 管理临床前研究期间产生的大量资料的需求日益增加
      • 生物製药公司扩大采用范围
    • 抑制因素
      • 缺乏熟练的专业人员
    • 机会
      • 人工智慧云实现了药物发现的简化和自动化方法
      • 研发投入不断增加
    • 任务
      • 资料集的可用性有限
  • 市场区隔分析
    • 我们提供什么：人工智慧软体提案药物发现的创新方法
    • 技术：在个人化护理中更多地采用情境感知处理
    • 流程：透过计算和预测能力显着增强药物发现流程
    • 应用：人工智慧设计的小分子药物在人体临床试验中的使用正在增加。
    • 治疗领域：在个人化癌症治疗的药物发现中更多地采用人工智慧。
    • 最终用户：在药物发现中更多地使用人工智慧，以加速製药和生物技术公司的药物发现过程
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章药物发现中的人工智慧市场：透过提供

  • 服务
  • 软体

第七章药物发现中的人工智慧市场：依技术分类

  • 情境感知处理
  • 机器学习
  • 自然语言处理

第八章药物发现中的人工智慧市场：按流程

  • 候选人的选择和检验
  • 命中识别和优先排序
  • 线索辨识/线索生成
  • 先导药物最适化
  • 目标识别和选择
  • 目标检验

第九章药物发现中的人工智慧市场：按应用分类

  • 生技药品设计与最佳化
  • 疾病识别和评估
  • 安全性、毒性和合规性评估
  • 小分子设计与优化
  • 疫苗设计和优化

第10章药物发现中的人工智慧市场（按治疗领域）

  • 循环系统疾病
  • 免疫肿瘤学
  • 代谢性疾病
  • 神经退化性疾病

第十一章药物发现中的人工智慧市场：按最终用户划分

  • 合约调查机构
  • 製药和生物技术公司
  • 研究中心以及学术和政府机构

第 12 章：美洲药物发现中的人工智慧市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十三章亚太地区药物发现人工智慧市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第14章：欧洲、中东和非洲药物发现中的人工智慧市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 默克建立两个策略联盟以加强人工智慧驱动的药物发现
    • In Silico的第二阶段计划的启动凸显了生成式人工智慧的发展势头
    • Google Cloud 宣布推出利用 AI 安全加速药物发现和精准医疗的解决方案
  • 战略分析和建议

第16章竞争组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-031BF22F953D

[196 Pages Report] The Artificial Intelligence in Drug Discovery Market size was estimated at USD 1.08 billion in 2023 and expected to reach USD 1.35 billion in 2024, at a CAGR 27.10% to reach USD 5.81 billion by 2030.

Artificial Intelligence in drug discovery refers to the application of machine learning algorithms and AI systems in the process of discovering, designing, and optimizing new drug compounds. These AI models play a pivotal role in streamlining the traditionally complex and time-consuming drug discovery process, thus facilitating advancements in the field of medicine. The market growth is propelled by the growing burden of chronic diseases worldwide and the rising adoption of AI across biopharmaceutical companies for heightened precision, speed, and effectiveness in drug discovery. Moreover, the increasing need to manage the large data generated during preclinical studies drives market growth. The need for more skilled AI professionals in healthcare and the high costs associated with implementing AI is influencing growth limitation. The limited availability of data sets is a pivotal challenge curtailing the growth of AI in drug discovery. The opportunities are poised in fields related to novel drug discovery mechanisms and personalized medicine. Technological advancement in the burgeoning areas of AI research for drug development creates a potentiality for enhanced drug discovery, disease understanding, and patient-specific treatments.

KEY MARKET STATISTICS
Base Year [2023] USD 1.08 billion
Estimated Year [2024] USD 1.35 billion
Forecast Year [2030] USD 5.81 billion
CAGR (%) 27.10%

Offering: AI Software propose a revolutionary approach to drug discovery

Within the field of drug discovery, Artificial Intelligence (AI) offers a robust range of services that expedite the process, enhance accuracy, and ultimately improve outcomes. These services majorly include structural analysis, drug repositioning, and pharmacodynamics modeling. AI software has catalyzed a digital revolution in drug discovery. Distinct software solutions have surfaced as a product of integrating AI into drug discovery. These software include predictive analytics, molecular docking, precision medicine, and modeling and analysis software to speed up matching a patient to the most effective.

Technology: Growing adoption of context-aware processing in personalized therapeutic

Context-aware processing is personalized, with AI algorithms cross-referencing genetic data, biomarkers, and disease indicators to suggest potential drug targets or bespoke treatments. Machine learning, another AI subfield, facilitates intelligent, unprogrammed decisions, predicting compound traits, patient reactions, and enhancing drug design. Natural language processing, meanwhile, harnesses the power of human language for data mining, assimilating information from academic sources to fortify data inclusivity. Context-aware processing offers personalized therapeutic recommendations, whereas machine learning drives the optimization of drug design. Conversely, natural language processing leverages large datasets to identify novel drug-disease associations. Rather than working in isolation, these technologies have convergent potentials, promising precise, expedited drug discovery.

Process: Significant augmentation in the drug discovery process with computational prowess and predictive capabilities

In the Artificial Intelligence (AI) world in drug discovery, candidate selection and validation is a crucial step in robustly assessing the potential success of prospective drug candidates. AI algorithms analyze molecular structures, predict their effect, and determine their viability. The next step involves hit identification and prioritization, prepping a list of promising drug candidates derived from AI screening. These hits are prioritized based on potency, selectivity, and safety. Following hit identification, the hit-to-lead identification or lead generation stage focuses on transforming the 'hits' into 'leads,' i.e., potential drug candidates that can be further optimized. Here, AI helps to evaluate and optimize leads with medicinal chemists testing and optimizing compounds. The next segment represents lead optimization, where potential drug candidates are enhanced for improved activity, specificity, and safety. This stage necessitates advanced AI technology to predict potential side effects and methodology to enhance drug efficacy. The drug discovery process also encompasses target identification and selection, which involves the choice of disease-modifying targets for the drug. The final stage is target validation, which verifies the selected target's role in the progression of the disease and its potential to be modulated by a drug. Artificial Intelligence continues revolutionizing drug discovery by augmenting each step with computational power and predictive capabilities. It significantly enhances drug discovery's efficiency and potential to deliver life-saving drugs to the market faster.

Application: Growing usage of AI-designed small molecule drugs for human clinical trials.

Biologics molecular-targeted drugs leverage AI for speedier and more accurate optimization, with AlphaFold demonstrating considerable protein prediction capabilities, expediting drug discovery. AI algorithms enhance disease identification and assessment by decoding patterns more accurately, allowing earlier interventions. Safety, toxicity, and compliance checks during drug development leverage AI to foresee toxicities, augmenting safety and decreasing costs/ Small molecule drug discovery, usually time-consuming, is being revolutionized by AI. Amidst COVID-19, efficient vaccine design and optimization are critical and facilitated by AI-enabled identification of viral pathogenic regions. Thus, AI is pivotal for pharmaceutical innovations, aiding in identifying diseases, designing therapeutics, and ensuring safety compliance.

Therapeutic Area: Rising adoption of AI in the drug discovery for personalized cancer treatment.

Artificial intelligence(AI) has been emerging as a transformative tool in cardiovascular disease management, ranging from early detection to personalized medication production. AI applications are seeing increased use in immuno-oncology, where they help classify and predict treatment responses. Companies and researchers are using AI to revolutionize the understanding and treatment of metabolic diseases, from diabetes to obesity. AI's potential to aid in diagnosing and developing treatments for neurodegenerative diseases has been recognized across the sector.

End User: Increasing use of AI in the drug discovery by pharmaceutical and biotechnology companies to accelerate their drug discovery process

Contract research organizations(CROs) leverage AI to significantly augment their drug discovery services, offering high-quality and efficient outcomes. CROs dealing with AI-powered drug discovery generally prefer solutions designed to streamline their workflow, accelerate the speed of discovery, and minimize human errors. Pharmaceutical and biotechnology companies, leading drug discovery drivers, show considerable affinity towards AI. AI facilitates these industries in expediting the drug discovery process, predicting drug response, and reducing costs associated with drug failure.

Research centers and academic & government institutes are increasingly capitalizing on AI's potential in drug discovery. The preference here lies in AI's power to predict potential drug candidates, minimize trial and error instances, and absorb vast data for precise research. Although the degree of AI utilization varies among end users, its positive impact is unmistakable. AI's potential to revolutionize drug discovery through its precision, speed, and cost-effectiveness is increasingly recognized across the field.

Regional Insights

The U.S. stands at the forefront of integrating AI into drug discoveries, fuelled by an active start-up environment and robust governmental funding. Canada echoes this dedication with considerable investment in AI-driven discovery platforms. European countries, such as the UK, France, and Germany, are leveraging AI and data science to revolutionize drug discovery procedures, attributed to strategic collaboration between academic institutions and the pharmaceutical industry. With China, Japan, and India at the helm, Asia-Pacific offers compelling dynamics. China's massive AI investment, paired with Japan's excellence in pharmaceutical research, is fostering the adoption of AI in drug discovery. In India, governmental support and an expanding IT sector are moving towards AI in drug discoveries. The U.S., China, and EU lead in patent claims for AI drug discoveries, representing consistent innovation in their pharmaceutical industries.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Artificial Intelligence in Drug Discovery Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Artificial Intelligence in Drug Discovery Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Artificial Intelligence in Drug Discovery Market, highlighting leading vendors and their innovative profiles. These include Aria Pharmaceuticals, Inc., Atomwise, Inc., BenevolentAI Limited, BenevolentAI SA, BioSymetrics Inc., BPGbio Inc., Butterfly Network, Inc., Cloud Pharmaceuticals, Inc., Cyclica Inc., Deargen Inc., Deep Genomics Incorporated, Envisagenics, Inc., Euretos Services BV, Exscientia PLC, Insilico Medicine, Insitro, Inc., International Business Machines Corporation, InveniAI LLC, Microsoft Corporation, Novartis AG, NVIDIA Corporation, Oracle Corporation, Owkin, Inc., Verge Genomics Inc., and XtalPi Inc..

Market Segmentation & Coverage

This research report categorizes the Artificial Intelligence in Drug Discovery Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Offering
    • Services
    • Software
  • Technology
    • Context-Aware Processing
    • Machine Learning
    • Natural Language Processing
  • Process
    • Candidate Selection & Validation
    • Hit Identification & Prioritization
    • Hit-to-lead Identification/ Lead generation
    • Lead Optimization
    • Target Identification & Selection
    • Target Validation
  • Application
    • Biologics Design & Optimization
    • Disease Identification & Assessment
    • Safety, Toxicity, & Compliance Assessment
    • Small Molecule Design & Optimization
    • Vaccine Design & Optimization
  • Therapeutic Area
    • Cardiovascular Disease
    • Immuno-Oncology
    • Metabolic Diseases
    • Neurodegenerative Diseases
  • End User
    • Contract Research Organizations
    • Pharmaceutical & Biotechnology Companies
    • Research Centers and Academic & Government Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Artificial Intelligence in Drug Discovery Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Artificial Intelligence in Drug Discovery Market?

3. What are the technology trends and regulatory frameworks in the Artificial Intelligence in Drug Discovery Market?

4. What is the market share of the leading vendors in the Artificial Intelligence in Drug Discovery Market?

5. Which modes and strategic moves are suitable for entering the Artificial Intelligence in Drug Discovery Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Demand to Control Drug Discovery Process and Reduce Cost
      • 5.1.1.2. Increasing Need to Manage the Large Data Generated During Preclinical Studies
      • 5.1.1.3. Increasing Adoption across Biopharmaceutical Companies
    • 5.1.2. Restraints
      • 5.1.2.1. Unavailability of Skilled Professionals
    • 5.1.3. Opportunities
      • 5.1.3.1. AI Cloud to Create a Streamlined and Automated Approach in Drug Discovery
      • 5.1.3.2. Increasingly Growing R&D Investments
    • 5.1.4. Challenges
      • 5.1.4.1. Limited Availability of Data Sets
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offering: AI Software propose a revolutionary approach to drug discovery
    • 5.2.2. Technology: Growing adoption of context-aware processing in personalized therapeutic
    • 5.2.3. Process: Significant augmentation in the drug discovery process with computational prowess and predictive capabilities
    • 5.2.4. Application: Growing usage of AI-designed small molecule drugs for human clinical trials.
    • 5.2.5. Therapeutic Area: Rising adoption of AI in the drug discovery for personalized cancer treatment.
    • 5.2.6. End User: Increasing use of AI in the drug discovery by pharmaceutical and biotechnology companies to accelerate their drug discovery process
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Artificial Intelligence in Drug Discovery Market, by Offering

  • 6.1. Introduction
  • 6.2. Services
  • 6.3. Software

7. Artificial Intelligence in Drug Discovery Market, by Technology

  • 7.1. Introduction
  • 7.2. Context-Aware Processing
  • 7.3. Machine Learning
  • 7.4. Natural Language Processing

8. Artificial Intelligence in Drug Discovery Market, by Process

  • 8.1. Introduction
  • 8.2. Candidate Selection & Validation
  • 8.3. Hit Identification & Prioritization
  • 8.4. Hit-to-lead Identification/ Lead generation
  • 8.5. Lead Optimization
  • 8.6. Target Identification & Selection
  • 8.7. Target Validation

9. Artificial Intelligence in Drug Discovery Market, by Application

  • 9.1. Introduction
  • 9.2. Biologics Design & Optimization
  • 9.3. Disease Identification & Assessment
  • 9.4. Safety, Toxicity, & Compliance Assessment
  • 9.5. Small Molecule Design & Optimization
  • 9.6. Vaccine Design & Optimization

10. Artificial Intelligence in Drug Discovery Market, by Therapeutic Area

  • 10.1. Introduction
  • 10.2. Cardiovascular Disease
  • 10.3. Immuno-Oncology
  • 10.4. Metabolic Diseases
  • 10.5. Neurodegenerative Diseases

11. Artificial Intelligence in Drug Discovery Market, by End User

  • 11.1. Introduction
  • 11.2. Contract Research Organizations
  • 11.3. Pharmaceutical & Biotechnology Companies
  • 11.4. Research Centers and Academic & Government Institutes

12. Americas Artificial Intelligence in Drug Discovery Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Artificial Intelligence in Drug Discovery Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Artificial Intelligence in Drug Discovery Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery
    • 15.3.2. Launch of Insilico's Phase II Program Highlights Generative AI Momentum
    • 15.3.3. Google Cloud Launches AI-powered Solutions to Safely Accelerate Drug Discovery and Precision Medicine
  • 15.4. Strategy Analysis & Recommendation

16. Competitive Portfolio

  • 16.1. Key Company Profiles
  • 16.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET RESEARCH PROCESS
  • FIGURE 2. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET DYNAMICS
  • FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 22. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 27. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 28. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CONTEXT-AWARE PROCESSING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CONTEXT-AWARE PROCESSING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CANDIDATE SELECTION & VALIDATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CANDIDATE SELECTION & VALIDATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION & PRIORITIZATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION & PRIORITIZATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT-TO-LEAD IDENTIFICATION/ LEAD GENERATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT-TO-LEAD IDENTIFICATION/ LEAD GENERATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION & SELECTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION & SELECTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS DESIGN & OPTIMIZATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS DESIGN & OPTIMIZATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISEASE IDENTIFICATION & ASSESSMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISEASE IDENTIFICATION & ASSESSMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY SAFETY, TOXICITY, & COMPLIANCE ASSESSMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY SAFETY, TOXICITY, & COMPLIANCE ASSESSMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DESIGN & OPTIMIZATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DESIGN & OPTIMIZATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY VACCINE DESIGN & OPTIMIZATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY VACCINE DESIGN & OPTIMIZATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY IMMUNO-ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY IMMUNO-ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY METABOLIC DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY METABOLIC DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 87. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 88. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 91. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 92. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 93. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 94. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 95. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 96. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 97. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 98. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 99. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 100. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 101. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 102. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 103. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 104. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 105. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 106. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 107. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 108. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 109. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 110. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 111. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 112. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 113. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 114. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 115. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 116. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 117. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 118. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 119. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 120. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 121. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 122. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 123. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 124. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 125. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 126. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 127. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 128. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 129. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 130. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 131. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 132. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 133. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 134. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 135. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 136. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 137. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 138. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 139. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 140. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 156. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 158. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 160. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 162. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 163. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 164. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 166. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 167. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 168. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 169. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 170. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 171. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 172. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 173. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 174. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 175. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 176. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 177. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 178. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 179. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 180. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 181. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 182. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 183. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 184. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 185. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 186. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 187. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 188. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 189. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 190. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 191. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 192. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 193. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 194. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 195. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 196. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 197. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 198. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 199. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 200. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 201. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 202. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 203. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 204. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 205. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 206. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 207. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 208. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 209. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 210. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 211. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 212. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 213. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 214. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 215. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 216. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 217. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 218. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 219. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 220. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 221. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 222. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 223. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 224. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 225. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 226. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 228. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 230. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 232. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 234. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 236. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 238. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 239. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 240. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 241. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 242. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 243. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 244. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 245. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 246. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 247. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 248. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 249. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 250. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 251. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 252. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 254. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 256. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 258. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 260. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 262. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 263. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 264. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 265. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 266. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 267. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 268. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 269. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 270. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 271. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 272. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 273. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 274. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 275. THAILAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 276. THAILAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 277. THAILAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 278. THAILAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 279. THAILAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-20